^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Urothelial Cancer

    Related cancers:
    1d
    Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (clinicaltrials.gov)
    P1, N=94, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    carboplatin • paclitaxel • veliparib (ABT-888)
    1d
    DK222 Study at Hopkins (clinicaltrials.gov)
    P1, N=6, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    PD-L1 (Programmed death ligand 1)
    1d
    Korean Prospective Upper Tract Urothelial Carcinoma Cohort (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Samsung Medical Center
    New trial
    1d
    Fluorescent Ureterorenoscopy-Assisted Thulium:YAG and Holmium:YAG Dual-Laser Ablation for Upper Urinary Tract Urothelial Carcinoma: Results of the FLUAM Trial. (PubMed, Ann Surg Oncol)
    This study provided evidence for the potential benefits and efficacy of this treatment option for selected patients with UTUC.
    Journal
    |
    UroVysion™ Bladder Cancer Kit (UroVysion Kit)
    2d
    Prognostic Significance of Tertiary Lymphoid Structure-Like Lymphocyte Aggregates in Routine Histopathological Examination in Bladder Cancer. (PubMed, Int J Urol)
    The findings of this study suggest that the presence of TLS-like lymphocyte aggregates observed on routinely used hematoxylin and eosin-stained slides of RC specimens may be an important predictor of survival outcomes after RC.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    2d
    LIAM Mc: Linking In With Advice and Supports for Men Impacted by Metastatic Cancer (clinicaltrials.gov)
    P=N/A, N=72, Active, not recruiting, University College Cork | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2025 --> Mar 2026
    Enrollment closed • Trial primary completion date
    2d
    Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Peking University Cancer Hospital & Institute | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    2d
    NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Nov 2026
    Trial completion date • Platinum resistant
    |
    PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    2d
    KEYMAKER-U04 Substudy: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=390, Completed, Merck Sharp & Dohme LLC | Recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Padcev (enfortumab vedotin-ejfv) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
    2d
    CHASIT (2024-516940-24-00`2022-000514-33)
    P1/2, N=58, Recruiting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Bavencio (avelumab)
    2d
    Decoding the metabolic-immune axis for novel therapeutics in bladder cancer. (PubMed, Biochim Biophys Acta Rev Cancer)
    In particular, the dynamic interplay between tumor cell metabolic reprogramming and the immune suppressive tumor microenvironment, collectively termed the "metabolic-immune axis", constitutes a major challenge underlying drug resistance. This review summarizes how this axis, through mechanisms such as enhanced glycolysis and abnormal amino acid/lipid metabolism, influences bladder cancer progression and treatment responsiveness, thereby establishing a theoretical framework for future research directions.
    Review • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • CDH1 (Cadherin 1) • RASSF1 (Ras Association Domain Family Member 1)
    |
    TP53 mutation • FGFR3 mutation